103148-92-1 Usage
General Description
2,3-Dihydro-1-<(triphenylphosphoranyliden)acetyl>indol, also known as Phosindol, is a chemical compound with the molecular formula C34H27NOP. It is a phosphorus-containing indole derivative that is commonly used in organic synthesis and medicinal chemistry. Phosindol has been studied for its potential anti-inflammatory and anti-cancer properties, as well as its ability to inhibit the growth of certain cancer cells. It is also used as a ligand in metal-catalyzed reactions and as a building block for the synthesis of complex organic molecules. Due to its diverse range of applications, Phosindol is an important compound in the field of organic chemistry and drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 103148-92-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,1,4 and 8 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 103148-92:
(8*1)+(7*0)+(6*3)+(5*1)+(4*4)+(3*8)+(2*9)+(1*2)=91
91 % 10 = 1
So 103148-92-1 is a valid CAS Registry Number.
103148-92-1Relevant articles and documents
The synthesis of α,α-disubstituted α-amino acids via ichikawa rearrangement
Szczes?niak, Piotr,Pieczykolan, Micha?,Stecko, Sebastian
, p. 1057 - 1074 (2016/02/19)
An approach to α,α-disubstituted α-amino acids is reported. The key step is allyl cyanate-to-isocyanate rearrangement. As demonstrated, the resultant allyl isocyanates can be directly trapped with various nucleophiles, for instance, alcohols, amines, and organometallic reagents, to provide a broad range of N-functionalized allylamines. The developed method has been successfully applied in the synthesis of two bioactive peptides: 2-aminoadamantane-2-carboxylic acid derived P2X7-evoked glutamate release inhibitor and 4-amino-tetrahydropyranyl-4-carboxylic acid derived dipeptide GSK-2793660, which is currently in clinical trials as cathepsin C inhibitor for the treatment of cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis.
